M

MGI Tech Co Ltd
SSE:688114

Watchlist Manager
MGI Tech Co Ltd
SSE:688114
Watchlist
Price: 48.3 CNY -6.58% Market Closed
Market Cap: 20.1B CNY
Have any thoughts about
MGI Tech Co Ltd?
Write Note

MGI Tech Co Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

MGI Tech Co Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
M
MGI Tech Co Ltd
SSE:688114
Accounts Receivables
ÂĄ697.2m
CAGR 3-Years
-9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Accounts Receivables
ÂĄ8.8B
CAGR 3-Years
19%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Accounts Receivables
ÂĄ2.6B
CAGR 3-Years
25%
CAGR 5-Years
25%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Accounts Receivables
ÂĄ6.1B
CAGR 3-Years
28%
CAGR 5-Years
47%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Accounts Receivables
ÂĄ4.1B
CAGR 3-Years
32%
CAGR 5-Years
31%
CAGR 10-Years
33%
W
WuXi XDC Cayman Inc
HKEX:2268
Accounts Receivables
ÂĄ853.3m
CAGR 3-Years
225%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

MGI Tech Co Ltd
Glance View

Market Cap
19.9B CNY
Industry
Life Sciences Tools & Services

MGI Tech Co Ltd, a key player in the genomics industry, emerged from the bustling biotech hub of Shenzhen, China, and swiftly carved a niche for itself with cutting-edge sequencing technology. Founded in 2016 as a subsidiary of BGI Group, MGI has dedicated itself to developing advanced genetic sequencing platforms and related products. The company’s mission is clear: to empower life science research and healthcare by providing innovative tools that make sequencing faster, cheaper, and more accessible. At the core of MGI’s success is their proprietary platform sequencing technology, known as the DNBSEQ™, which has garnered attention for its high throughput and accuracy. This technology is pivotal to their business model, as it significantly reduces the cost of sequencing, giving MGI a competitive edge in the market. MGI's business thrives on a dual revenue stream, primarily from the sale of their state-of-the-art sequencing devices and from providing sequencing services. Their portfolio of sequencing platforms, ranging from benchtop sequencers like the MGISEQ-2000 to large-scale units, caters to a diverse clientele, including research institutions, healthcare providers, and industry giants. The company supports this with a robust after-sales service and supply of consumables required for continuous operation, such as reagents and sequencing kits. By embedding itself deeply into the operational frameworks of its clients, MGI not only boosts its device sales but also ensures a persistent revenue flow from ongoing service and supplies. This business model positions MGI Tech Co Ltd as a formidable force, continually driving advancements in genome technology while expanding its global footprint.

Intrinsic Value
39.36 CNY
Overvaluation 19%
Intrinsic Value
Price
M

See Also

What is MGI Tech Co Ltd's Accounts Receivables?
Accounts Receivables
697.2m CNY

Based on the financial report for Dec 31, 2023, MGI Tech Co Ltd's Accounts Receivables amounts to 697.2m CNY.

What is MGI Tech Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 3Y
-9%

Over the last year, the Accounts Receivables growth was 17%. The average annual Accounts Receivables growth rates for MGI Tech Co Ltd have been -9% over the past three years .

Back to Top